Key Updates in Health: FDA Approvals, Recalls, and New Treatments

The latest health news includes FDA approval of neffy, a needle-free alternative to EpiPen for allergic reactions, Perrigo recalling infant formula, bluetongue vaccination in France, vape development for migraines and asthma, FDA declining MDMA-based PTSD treatment, a swine flu case in Michigan, and extended review for Humacyte's blood vessel implant.

In recent developments in the health sector, the U.S. Food and Drug Administration has approved neffy, ARS Pharmaceuticals' nasal spray, as the first needle-free emergency treatment for severe allergic reactions. This nasal spray is seen as a revolutionary alternative to the widely used EpiPen. In another update, Perrigo has voluntarily recalled 16,500 cans of its infant formula sold at H-E-B Grocery Company and CVS due to potential health risks.

Meanwhile, France has extended its bluetongue vaccination campaign following two new outbreaks of a variant in ruminants in northern Europe. The French farm ministry acted swiftly after detecting the BTV3 bluetongue disease near the Belgian border. Additionally, North American companies developing vape-like devices for migraine and asthma treatments face the challenge of convincing both health authorities and patients of the efficacy and safety of their new products.

In other news, the FDA has declined to approve the first MDMA-based therapy for PTSD, citing insufficient data. The Michigan Department of Health and Human Services reported a human case of swine flu, with the source of exposure under investigation. Lastly, Humacyte announced that the FDA has extended its review of the company’s blood vessel implant, causing a notable drop in the company's shares.